デフォルト表紙
市場調査レポート
商品コード
1370374

病院感染治療薬市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
病院感染治療薬市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年10月15日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

市場概要:

世界の病院感染治療薬市場規模は2022年に118億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて4.8%の成長率(CAGR)を示し、2028年までに158億米ドルに達すると予測しています。

病院感染治療薬は、院内感染の治療に使用されるさまざまな医薬品を指します。これらの感染症は、病院、介護施設、リハビリ施設、その他の臨床現場で発症する可能性があり、通常は抗ウイルス薬、抗菌薬、抗真菌薬によって治療されます。抗菌薬には、バンコマイシン、カルバペネム系抗生物質、セファロスポリン、リネゾリド、アミノグリコシド系抗生物質、チゲサイクリンなどの細胞壁合成阻害薬やタンパク質合成阻害薬があります。抗真菌治療薬には、カスポファンギンやアムホテリシンBが含まれます。これらの薬剤は、院内肺炎、尿路感染(UTI)、胃腸障害、血流感染、手術部位感染などの予防に役立ちます。

院内感染症(HAD)の有病率の増加は、市場の成長を促進する主な要因の1つです。さらに、このような病気にかかりやすい老年人口の増加も市場成長の原動力となっています。病院やその他のヘルスケア機関における衛生設備の悪化に起因して、院内肺炎やその他の感染症の発生が大幅に増加しており、これが病院感染治療薬の需要増加に寄与しています。さらに、先進的な微生物創傷治療薬、被覆剤、ワクチンの開発など、さまざまな製品イノベーションが他の成長促進要因として作用しています。製品メーカーは、多剤耐性感染症に有効で、特定の症状を伴う感染症の治療に使用できる抗菌薬やパイプライン医薬品分子を開発しています。その他の要因としては、広範な研究開発(R&D)活動、ヘルスケアインフラの改善などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の病院感染治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか?
  • COVID-19が世界の病院感染治療薬市場に与えた影響は?
  • 主要な地域市場は?
  • 薬剤タイプ別の市場内訳は?
  • 適応症別の市場内訳は?
  • 業界のバリューチェーンにおける様々な段階とは?
  • 業界の主な促進要因と課題は何か?
  • 世界の病院感染治療薬市場の構造と主要プレーヤーは?
  • 業界の競合の程度は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 病院感染治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:薬剤タイプ別

  • 抗菌薬
    • 市場動向
    • 市場予測
  • 抗真菌薬
    • 市場動向
    • 市場予測
  • 抗ウイルス剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳:適応症別

  • 血流感染症
    • 市場動向
    • 市場予測
  • 尿路感染症
    • 市場動向
    • 市場予測
  • 手術部位感染
    • 市場動向
    • 市場予測
  • 肺炎
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Allergan Plc(AbbVie Inc.)
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG(Roche Holding AG)
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2022
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2022
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players
目次
Product Code: SR112023A2393

Abstract

Market Overview:

The global hospital infection therapeutics market size reached US$ 11.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.8 Billion by 2028, exhibiting a growth rate (CAGR) of 4.8% during 2023-2028.

Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.

The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type and indication.

Breakup by Drug Type:

Anti-bacterial Drugs

Anti-fungal Drugs

Anti-viral Drugs

Others

Breakup by Indication:

Blood Stream Infections

Urinary Tract Infections

Surgical Site Infections

Pneumonia

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the indication?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hospital infection therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis